FDA hands down a par­tial hold for PhI/II tri­al of Blue­print’s CDK2 in­hibitor

The FDA is giv­ing one of Blue­print Med­i­cines’ tri­als a par­tial clin­i­cal hold.

On Fri­day, the Mass­a­chu­setts-based biotech said the FDA in­formed Blue­print two days …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER